WHO Launches Groundbreaking Online Repository for Evidence-Informed Decision-Making Tools

By HEOR Staff Writer

September 19, 2023

Evidence-Informed Decision-Making

The World Health Organization (WHO) has launched an innovative online repository of Evidence-Informed Decision-Making (EIDM) tools. This pioneering platform, the first of its kind, showcases WHO tools and external tools used by WHO to facilitate knowledge translation. It also highlights partner organisations involved in planning, managing, monitoring, and evaluating the process of evidence use and implementation.

Developed by the Evidence to Policy and Impact Unit of the Research for Health Department in the Science Division, in collaboration with the Evidence-Informed Policy Network (EVIPNet), the repository supports the unit’s EIDM capacity-sharing work. The platform complements the WHO evidence ecosystem framework published last year, specifically focusing on the policy/action cycle.

Navigating the Online Platform

The user-friendly online platform enables users to search and access EIDM methods and tools corresponding to each step of the policy/action cycle. Users can refine their searches using advanced functionalities to filter by document type, language, and publication date. The platform offers tools that span the clinical (or practice), public health, and health system domains.

Currently, the repository houses and maintains 75 tools, with continuous updates as new tools emerge. The Evidence to Policy and Impact Unit plans to actively add more tools to the repository, employing a scoping literature review and other steps.

The ultimate goal of EIDM and the work of EVIPNet is to support WHO staff and Member States in applying rigorous, systematic, and transparent methods for the creation and application of research evidence in their day-to-day work. This will enable the organisation to successfully achieve the “Triple Billion” targets: a billion more people with universal health coverage, a billion more people protected from health emergencies, and a billion more people with better health and well-being.

Reference url

Recent Posts

cemdisiran gMG treatment
Breakthrough in cemdisiran gMG treatment Advances Regulatory Landscape

By João L. Carapinha

June 25, 2026

Cemdisiran gMG treatment has cleared a critical hurdle after the FDA and EMA accepted Regeneron’s regulatory submissions for review in anti-AChR antibody-positive generalized myasthenia gravis (gMG). The investigational siRNA therapy targeting complement protein C5 could become the first subcutan...
Trodelvy ADC approval
Advancements in Breast Cancer Treatment Following Trodelvy ADC Approval

By João L. Carapinha

June 25, 2026

The Trodelvy ADC approval by the European Commission delivers the first antibody-drug conjugate approved for first-line use in adults with unresectable or metastatic triple-negative breast cancer who are ineligible for PD-1 or PD-L1 inhibitors. This
Cemiplimab Cervical Cancer Access
Cemiplimab Cervical Cancer Access Navigating Treatment and Value

By João L. Carapinha

June 24, 2026

Cemiplimab Cervical Cancer Access has been endorsed by NICE for adults with recurrent or metastatic cervical cancer that has progressed after platinum-based chemotherapy, provided patients have not previously received immunotherapy. The final draft guidance confirms that this PD-1 inhibitor deliv...